High Note Wealth’s ADMA Biologics ADMA Stock Holding History

High Note Wealth’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-236	Closed	-$4.68K	–	877
2025 Q1	$4.68K	Buy	+236	New	+$4.08K	﹤0.01%	444

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

High Note Wealth's ADMA Position: Q2 2025 in Review

High Note Wealth sold out of ADMA Biologics (ADMA) in Q2 2025, closing a stake of 236 shares — an estimated $4.68K sold.

High Note Wealth first reported a position in ADMA in Q1 2025 and held it in 1 quarter. The position peaked at $4.68K in Q1 2025. 368 funds tracked by Wall St. Rank hold ADMA as of Q2 2025.

High Note Wealth reported no remaining ADMA Biologics position as of Q2 2025 after selling out during the quarter.
High Note Wealth sold 236 ADMA Biologics shares in Q2 2025, an estimated $4.68K.
High Note Wealth first reported a position in ADMA Biologics in Q1 2025 and held it in 1 quarter.
High Note Wealth's ADMA Biologics position peaked at $4.68K in Q1 2025.
368 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2025.

Based on High Note Wealth's 13F filing for Q2 2025, filed 23 Jul 2025.